Tenapanor is a drug developed by Ardelyx which acts as an inhibitor of the sodium-proton exchanger NHE3. This antiporter protein is found in the kidney and intestines and normally acts to regulate the levels of sodium absorbed and secreted by the body. When administered orally tenapanor selectively inhibits sodium uptake in the intestines limiting the amount absorbed from food and thereby reduces levels of sodium in the body.
This page contains content from the copyrighted Wikipedia article "Tenapanor"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
